Board Certified in Surgery
Works for Specialty Center
Hyperthermic Intraperitoneal Chemotherapy
Dessureault was the surgeon involved in Moffitt’s recent groundbreaking study that detailed the benefits to patients of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, also known as HIPEC.
Patients who returned for a second round of treatment in the study survived almost three times as long as those who underwent only one procedure.
As a surgeon in the department of gastrointestinal oncology, her clinical and research interests also include vaccines that focus on reversing tumor-induced immune suppression.
Dessureault serves as associate professor at the University of South Florida’s College of Medicine. She first arrived at the school in 1999 for a fellowship in surgical oncology. She has won the Society of Surgical Oncology Young Investigator Award and the American Society of Clinical Oncology Career Development Award.
She graduated from the Dalhousie University School of Medicine in Halifax, Nova Scotia. She did a surgical residency at the University of Toronto, where she also completed a doctorate in the surgical scientist program and graduated as valedictorian of her class.
Disclaimer: Dr. Sophie Dessureault has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.
View our resources for patients and familiesGet Help Today